Alterity Therapeutics (ATHE) Stock: Buy, Sell, or Hold?
ATHE - Alterity Therapeutics Limited American Depositary Shares
$4.05
-0.06 (-1.46%)
▼
5d:
-10.4%
30d:
-17.52%
90d:
-1.46%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 27, 2026
0d
Get Alerted When ATHE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATHE is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATHE is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATHE is currently trading at $4.05, which is considered oversold relative to its 30-day fair value range of $4.37 to $4.73.
Technical Outlook: Technically, ATHE is showing sideways momentum. The price is currently testing key support at $4.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.25 (+227.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATHE is showing sideways momentum. The price is currently testing key support at $4.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.25 (+227.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.37 -
$4.73
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 227.2% below Wall St target ($13.25)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.37 -
$4.73
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.05
Resistance Level
$4.83
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.55
Wall Street Target
$13.25
(+227.2%)
Revenue Growth (YoY)
-79.0%
Share & Embed Analysis
Last updated: September 13, 2026 5:36 AM ET
Data refreshes hourly during market hours. Next update: 6:36 AM
Data refreshes hourly during market hours. Next update: 6:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATHE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$34 | 52 HOLD |
